Berotralstat hydrochloride

Berotralstat Hydrochloride is a medication used in the treatment of hereditary angioedema, a rare genetic disorder characterized by episodes of severe swelling. It is marketed under the brand name Orladeyo by BioCryst Pharmaceuticals.

Mechanism of Action

Berotralstat hydrochloride works by inhibiting plasma kallikrein, an enzyme that plays a key role in the inflammatory response that leads to swelling in hereditary angioedema. By blocking this enzyme, berotralstat hydrochloride can prevent or reduce the severity of swelling episodes.

Uses

Berotralstat hydrochloride is approved for use in adults and children 12 years of age and older with hereditary angioedema. It is taken orally once daily.

Side Effects

Common side effects of berotralstat hydrochloride include abdominal pain, vomiting, diarrhea, back pain, and heartburn. Serious side effects can include liver damage.

History

Berotralstat hydrochloride was approved by the Food and Drug Administration (FDA) in December 2020, making it the first oral medication approved for the prevention of attacks in hereditary angioedema patients.

See Also

• Hereditary angioedema
• Plasma kallikrein
• BioCryst Pharmaceuticals
• Food and Drug Administration